AquaBounty salmon (back) have an added growth-hormone gene that sees them grow to market size in about half the time as unmodified salmon. Credit: AquaBounty/MCT/Newscom

When she saw the trailer for the documentary Genetic Roulette, Alison Van Eenennaam wanted to laugh, then cry. The film touts the risks of genetically engineered (GE) organisms, calling them “the most dangerous thing facing human beings in our generation”. For Van Eenennaam, a geneticist at the University of California, Davis, the scientifically unfounded assertions — that transgenic foods are responsible for increased incidence of autism, Alzheimer’s disease and type 2 diabetes in the United States — cannot be taken seriously. But the film reflects attitudes that have thwarted Van Eenennaam’s research into the genetic modification of animals to reduce food costs and improve quality.

“Twenty years ago, the technology was our hurdle,” says Mark Westhusin, who works on GE animals at Texas A&M University in College Station. “Now the technology is great and the sky is the limit,” he says, “but good luck getting money for GE animals.”

Inquiries by Nature reveal that fewer than 0.1% of research grants from the US Department of Agriculture (USDA) have gone to work on GE food animals since 1999, in part because of a poor public image. In one case, James Murray, another geneticist at the University of California, Davis, was told in 2003 that the USDA had rejected his proposal to develop a goat that produces milk rich in human lysozymes — enzymes that fight diarrhoeal disease — because the agency felt that “the general public would not accept such animals”.

Van Eenennaam once hoped to engineer a cow that produced milk rich in omega-3 fats, but the USDA rejected her proposals, and she ended the project because of a lack of funding. The agency now funds her work on conventional breeding techniques to create dairy cows without horns, sparing farmers the danger and expense of removing them. Van Eenennaam says that she might do better by disrupting the genes that lead to horns, but there is no money for that. “I’ve got plenty of funding now, but the project is completely inefficient compared to genetic engineering,” she says.

The technology is great and the sky is the limit, but good luck getting money.

The USDA supports research to improve livestock and agriculture, but a spokesperson says that it has not considered work on GE animals to be the best use of its funding. The US National Institutes of Health (NIH) occasionally supports research on transgenic pigs that model human diseases, but rarely funds proposals to produce drugs or vaccines in the milk of transgenic livestock. An NIH spokesperson says that decisions are based on many factors, including the needs of the research community.

For GE animals that have been developed despite these hurdles, market approval has stalled. On 27 September, Van Eenennaam was a panellist at a meeting in Washington DC, where advocates of GE animal research aired their frustrations with the US Food and Drug Administration (FDA), which has yet to issue a decision on any GE food animal submitted for approval (see ‘Off the table’). A fast-growing salmon developed by AquaBounty in Maynard, Massachusetts, has been under review since 1995; in 2010, an FDA scientific advisory panel evaluated 21 years of data on the fish and deemed it safe for the environment and human consumption (see Nature 467, 259; 2010), yet the agency has still not announced a final decision. The FDA will not comment on its process.


“AquaBounty has done everything they are legally required to do, and, yes or no, now we just want an official word from the FDA,” says Van Eenennaam, who was on the advisory panel. “We will never have investment in this field if there is no way to move it forward.” She was one of 56 biotechnology advocates who wrote to US President Barack Obama on 15 September, asking why there has been no update (see Letter to Obama ).

The White House has not responded, and AquaBounty’s salmon is swimming against the tide of politics. Legislation introduced last year in the US House of Representatives and the Senate would ban the FDA from approving it. The protest in Congress comes mainly from salmon-exporting states such as Alaska, Washington and Oregon, amid fears that an inexpensive new source of salmon would undermine the industry. Politicians also reference unforeseen dangers from GE foodstuffs.

The FDA evaluates animals as strictly as it does drugs. In the 17 years that the salmon has been under review, AquaBounty has spent more than US$60 million on, for example, showing that its allergenic potential is no greater than that of Atlantic fish. To ensure that the mainly sterile GE salmon can’t mate with native species, the company keeps them in multiwalled tanks on a mountain in Panama. If the fish were to be sold commercially, they would be reared similarly isolated from the ocean.

The prospects for research are better outside the United States. Last year, Murray moved his goat project to Brazil, where the government funds his research; the childhood diarrhoea that the goats’ milk is intended to treat is a serious problem in the north of the country. And China invested nearly $800 million in transgenic pigs, cattle, sheep and crops between 2008 and 2012, says Ning Li, director of the State Key Laboratories for AgroBiotechnology in Beijing. More than 20 GE food animals are in development in China, he says, including a fast-growing carp and cows that produce milk with reduced allergenic potential. However, a Chinese researcher who asked to remain anonymous because he did not have permission to speak to the press predicts that approval for the animals will lag because the government has not determined how to ensure that the products are safe.

Even in the United Kingdom, where public opposition to GE plants and animals has been fierce, researchers seem to be better off than their US counterparts. The Biotechnology and Biological Sciences Research Council (BBSRC) supports work on GE food animals, including chickens engineered to be resistant to the bird-flu virus. A BBSRC spokesperson told Nature: “We consider it important to fund research that provides a range of technological options that can be applied to the challenges that we face as a society.”

Table 7.6895 Off the table